1140964-99-3 Usage
Description
E-7449 is a dual inhibitor of PARP1/2 and tankyrase1/2, which are enzymes involved in DNA damage and canonical Wnt/β-catenin signaling, respectively. It has been shown to exhibit anti-tumor activity in BRCA-deficient in vivo models.
Uses
Used in Pharmaceutical Industry:
E-7449 is used as an anti-tumor agent for its ability to inhibit PARP1/2 and tankyrase1/2, which play roles in DNA damage and canonical Wnt/β-catenin signaling. This makes it a potential therapeutic option for cancer treatment, particularly in BRCA-deficient in vivo models.
Used in Cancer Research:
E-7449 is used as a research tool for studying the roles of PARP1/2 and tankyrase1/2 in cancer development and progression. By inhibiting these enzymes, researchers can gain insights into the underlying mechanisms of cancer and identify potential targets for therapeutic intervention.
Used in Drug Development:
E-7449 is used as a lead compound in the development of new cancer therapies. Its dual inhibition of PARP1/2 and tankyrase1/2 makes it a promising candidate for further research and optimization to improve its efficacy and safety profile in the treatment of various types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1140964-99-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,0,9,6 and 4 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1140964-99:
(9*1)+(8*1)+(7*4)+(6*0)+(5*9)+(4*6)+(3*4)+(2*9)+(1*9)=153
153 % 10 = 3
So 1140964-99-3 is a valid CAS Registry Number.
1140964-99-3Relevant articles and documents
PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
-
Page/Page column 26, (2009/04/24)
The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.
